Oppenheimer analyst Akiva Felt maintained an Outperform rating on Neuroderm (NASDAQ:NDRM) and slightly raised his price target to $19 (from $18), which implies …
In a research report issued today, Roth Capital analyst Scott Henry reiterated a Buy rating on Neuroderm (NASDAQ:NDRM) with a $17.50 price target, …
SummaryNDRM is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system, or CNS, disorders through proprietary formulations based on existing drugs …